Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ORIC |
---|---|---|
09:32 ET | 4189 | 7.57 |
09:34 ET | 830 | 7.45 |
09:36 ET | 100 | 7.45 |
09:39 ET | 1000 | 7.5 |
09:41 ET | 2155 | 7.51 |
09:43 ET | 100 | 7.56 |
09:45 ET | 954 | 7.58 |
09:50 ET | 100 | 7.57 |
09:57 ET | 841 | 7.57 |
09:59 ET | 1600 | 7.58 |
10:01 ET | 533 | 7.62 |
10:03 ET | 1830 | 7.65 |
10:06 ET | 3000 | 7.65 |
10:08 ET | 200 | 7.7 |
10:10 ET | 100 | 7.7 |
10:12 ET | 800 | 7.73 |
10:14 ET | 100 | 7.76 |
10:15 ET | 200 | 7.75 |
10:17 ET | 1482 | 7.82 |
10:19 ET | 200 | 7.83 |
10:21 ET | 100 | 7.85 |
10:24 ET | 200 | 7.85 |
10:26 ET | 1012 | 7.855 |
10:28 ET | 500 | 7.83 |
10:30 ET | 1000 | 7.815 |
10:32 ET | 768 | 7.805 |
10:33 ET | 1347 | 7.82 |
10:35 ET | 800 | 7.825 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Oric Pharmaceuticals Inc | 507.0M | -4.3x | --- |
Third Harmonic Bio Inc | 501.2M | -16.1x | --- |
Corbus Pharmaceuticals Holdings Inc | 513.1M | -7.0x | --- |
Mind Medicine (MindMed) Inc | 500.2M | -2.5x | --- |
Neurogene Inc | 499.2M | -8.4x | --- |
Astria Therapeutics Inc | 492.6M | -3.9x | --- |
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $507.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 67.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-1.81 |
Book Value | $4.08 |
P/E Ratio | -4.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.